ERBB2 and neoplasm: To assess the safety of anti-HER2 CAR-TILs in an immune-competent and spontaneous tumor model before the first-time-in-man trial (FTIM), we conducted a first-in-dog (FIDO) trial that recruited four companion dogs with high-grade cancer (two with squamous carcinoma and two with melanoma).